SP1 and ovarian carcinoma: Beyond SP1-induced MCF2L-AS1, which activates the IGF2/MEK/ERK pathway (101), SP1 also transcribes multidrug resistance-associated proteins (MRPs) and key enzymes involved in arachidonic acid (AA) metabolism (e.g., 12-lipoxygenase), thereby promoting chemoresistance and metastasis in ovarian cancer (102).